{"links":{"html":"https://www.erudio.com/reports/furvent-nct05607550","json":"https://www.erudio.com/reports/furvent-nct05607550.json","markdown":"https://www.erudio.com/reports/furvent-nct05607550.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"furvent-05607550"}},"request":"https://www.erudio.com/contact?report=furvent-05607550"},"offer":{"cited_commentary_sources":15,"verified_hcp_statements":30,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":750,"identity_verified_people":11,"optional":true,"price_per_verified_person_usd":15,"price_usd":165,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"furvent-nct05607550"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=furvent-05607550","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/furvent-nct05607550","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-18T21:30:16.992553Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":0},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR)"},{"claim_count":7,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":3,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":5,"title":"Positioning among first-line alternatives and combination strategies"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":3,"title":"Earlier furmonertinib evidence and dose uncertainty"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"Access, administration and the chemotherapy-free treatment need"},{"claim_count":7,"coverage":"discussed","id":"A4","source_count":7,"title":"Prospective expectations and reactions to the program update"}],"counts":{"cited_sources":15,"claims_by_expression_type":{"comparison":4,"interpretation":6,"opinion":5,"question":1,"restatement":5,"uncertainty":7,"unspecified":2},"claims_by_kind":{"attributed_opinion":16,"source_observation":14},"clinician_statements":20,"evidence_units":24,"findings":5,"people_cited":12,"people_identity_verified":11,"people_total":13,"screened_sources":20,"verified_claims":30},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":3},"has_counterview":true,"limitations":3,"links":{"context":4,"support":6},"ma_question":true,"named_voices":5,"passages":7,"sources":3,"sources_by_kind":{"commentary":3}},"title":"The endpoint update prompted different readings of clinical usefulness"},{"id":"F2","structure":{"claims":9,"claims_by_group":{"comparisons":3,"experience":0,"questions":3,"restated":1,"views":2},"has_counterview":false,"limitations":3,"links":{"context":2,"support":9},"ma_question":true,"named_voices":5,"passages":7,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Regimen choice, not only agent choice, shapes first-line positioning"},{"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":0},"has_counterview":false,"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Earlier activity did not resolve dose–tolerability questions"},{"id":"F4","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":0,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"CNS evidence, administration and access remain practical differentiators"},{"id":"F5","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":4},"has_counterview":false,"limitations":3,"links":{"context":0,"support":8},"ma_question":false,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Earlier interest was anticipatory and sometimes explicitly conditional"}],"medical_affairs_question":"How should statistical evidence and possible clinical usefulness be discussed without treating unquantified additional observations as confirmation?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Interpreting the update without converting opinion into evidence"},{"id":"section-2","level":2,"title":"Comparing treatment strategies rather than ranking agents alone"},{"id":"section-3","level":2,"title":"Earlier response signals versus unresolved dose and gastrointestinal toxicity"},{"id":"section-4","level":2,"title":"CNS activity, route of administration and access"},{"id":"section-5","level":2,"title":"Keeping prospective interest separate from outcome judgments"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":3}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F5","shared_claims":3}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":3}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-18T21:30:16.992553Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-18T21:58:08Z","record_hash":"c6a9ae9f17b3cdbbc7ddb47e52097a1e9f455d6ac0ae159d877a46b0639a1d18","release_hash":"6e44291e463f522bcf47f7c46f65b0df707284b8e74fbd1c24918d372291326c","report_id":"erudio-nct05607550","run_id":"22292ff1-3f36-4f57-8e1e-c0ec832d86b8","schema_version":"5.0","slug":"furvent-05607550","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"HCP commentary report on Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) (NCT05607550). Trial question: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT). Aspects: Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR) (discussed, 6 verified views); Secondary endpoints (discussed, 7 verified views); Population and setting (discussed, 3 verified views); The comparison (discussed, 7 verified views); Safety and tolerability (discussed, 5 verified views); Design and conduct (discussed, 4 verified views); Positioning among first-line alternatives and combination strategies (discussed, 9 verified views); Earlier furmonertinib evidence and dose uncertainty (discussed, 4 verified views); Access, administration and the chemotherapy-free treatment need (discussed, 2 verified views); Prospective expectations and reactions to the program update (discussed, 7 verified views). 20 sources screened, 15 cited. The sources reviewed for this edition only; not all HCPs or all public discussion.","meta_description":"20 sources screened · 30 verified statements (20 from speakers with a confirmed clinical role) from 15 sources · 5 findings. Updated Oct 18, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-18T21:58:08Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":20},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Out of scope: 2 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","2 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits apply, so some matching discussion may be missing.","The report describes the sources reviewed for this edition, not the distribution of HCP opinion. Repeated appearances of the same statement do not establish independent agreement.","No full FURVENT results publication or protocol was available. The reported OS trend and response and investigator-assessed PFS observations lack effect sizes in the posts, limiting interpretation of clinical benefit.","Earlier FAVOUR observations and second-line-plus furmonertinib data provide context but cannot establish FURVENT's first-line efficacy, dose comparison or safety.","Matching regulatory labeling was not available for the furmonertinib doses or chemotherapy regimen. Regulatory descriptions in commentary were not independently established.","Some contributions came from accounts or an organization rather than confirmed individual HCPs. Sharing a linked article does not establish endorsement of its statements.","Dated descriptions of standard care, accrual hopes and anticipated data timing are not verification of current guidance or completed milestones."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":15},"count":15,"evidence_window":{"end":"2026-10-07","start":"2023-09-10"},"retrieval_snapshot":"2026-10-18T19:12:54.295091Z","timeline":[{"count":3,"week":"2023-W36"},{"count":1,"week":"2024-W09"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W15"},{"count":1,"week":"2024-W47"},{"count":1,"week":"2024-W52"},{"count":1,"week":"2025-W42"},{"count":2,"week":"2025-W52"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W37"},{"count":4,"week":"2026-W41"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05607550:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05607550:context","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1700733675313480170:6eff8732-73ab-4c39-accf-27d6ae7eaf7f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1700735957665030552:1f374bea-5cd3-4103-be3f-988320e23929","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1700835154623873403:8da0f925-0ed5-4e5d-8f03-3bddc788352d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1763667311968264599:d37d0263-01d9-40c3-8a85-bfd95ef88607","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1778840389085966800:c4189ca1-8ff9-41c5-97e0-b4506a137a9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1860475082394734801:310ff8ed-ffde-46bf-8649-06c2c83b9041","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1873323897845936207:ca495d4f-8ae9-42ba-9775-dd41920bc6e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1904935813499977822:505a5059-531f-4f7b-add1-3f3bec1456aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1975719944886051167:f61ebedf-711c-4a17-8a84-45e5da8264bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1977732432959799772:ba0cb5d3-c4e2-4292-81a9-94ebf1d1586d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979813586341147121:0c0b2092-05ee-4d08-b85e-99dd60db55ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2004657275114287267:ead24d00-6abf-409a-81ef-908c3e6dd017","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2004663762259767492:e3e171f6-be2b-4fdc-a135-5f295382326c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060767153796833711:3edd6f32-15cf-4ea2-bb4a-82e8b43a28a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097127042458304648:9239c772-9b21-42d6-add1-173901b6f747","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107496355312583092:c751921a-c565-4d68-a1d4-1ba13d1d5b1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107622763527893500:d07aa8df-a8b8-42ab-928d-0192272747db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107818022488756527:b5260381-7fd6-46b3-b5ba-3bedee294bcf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107910589398098085:43fc6aa1-e936-482c-a358-bab2ad9cc819","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4ga-xOICUFg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":19,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":20},"count":20,"evidence_window":{"end":"2026-10-07","start":"2023-09-10"},"retrieval_snapshot":"2026-10-18T19:12:54.295091Z","timeline":[{"count":3,"week":"2023-W36"},{"count":1,"week":"2024-W09"},{"count":1,"week":"2024-W12"},{"count":2,"week":"2024-W15"},{"count":1,"week":"2024-W47"},{"count":1,"week":"2024-W52"},{"count":1,"week":"2025-W13"},{"count":1,"week":"2025-W41"},{"count":2,"week":"2025-W42"},{"count":2,"week":"2025-W52"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W37"},{"count":4,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: furmonertinib 240 mg oral, daily","status":"unmapped"},{"reason":"Unmapped registry intervention: furmonertinib 160 mg oral, daily","status":"unmapped"},{"reason":"Unmapped registry intervention: platinum-based chemotherapy","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Metastatic Non-Small Cell Lung Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Advanced Non-Small Cell Lung Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: EGFR Exon 20 Mutations","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)","A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)"],"brief_title":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)","collaborators":["Allist Pharmaceuticals, Inc."],"conditions":["Metastatic Non-Small Cell Lung Cancer","Advanced Non-Small Cell Lung Cancer","EGFR Exon 20 Mutations"],"enrollment":{"count":398,"type":"ACTUAL"},"interventions":[{"name":"furmonertinib 240 mg oral, daily","synonyms":["AST2818"],"type":"DRUG"},{"name":"furmonertinib 160 mg oral, daily","synonyms":["AST2818"],"type":"DRUG"},{"name":"platinum-based chemotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05607550","official_title":"A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2025-08-15","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Progression Free Survival (PFS) determined by blinded independent central review (BICR)","timeFrame":"Up to 32 months after first dose"}],"registry_last_updated":"2025-06-22","registry_url":"https://clinicaltrials.gov/study/NCT05607550","short_name":"FURVENT","short_name_basis":"registry_title","sponsor":"ArriVent BioPharma, Inc.","start_date":{"date":"2023-06-01","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"FURMO-004","type":"sponsor_study_id"},{"id":"2022-502977-41-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}